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Tumour regression predicts higher risk of sentinel
node involvement in thin cutaneous melanomas
SIR, Metastatic involvement of regional lymph nodes is one of
the most important prognostic factors in cutaneous malig-
nant melanoma (CMM).1,2 The sentinel lymph node biopsy
(SNB) has become widely established in several countries as a
technique for prognostic assessment. The surgical procedure
is not complicated and carries relatively low morbidity;
however, the indications for SNB are still a matter of debate.
Although metastatic involvement in patients with very thin
primary melanoma is rare, there have been several reported
cases.3,4 Melanomas showing histological evidence of regres-
sion are in some cases associated with a worse clinical course
than similar but nonregressing tumours.5–7 We therefore
examined the correlation of primary melanoma regression
and sentinel node positivity in patients with thin melanomas.
One hundred and thirty-four patients with melanoma with
a primary tumour thickness of 2Æ0 mm or less underwent
SNB at the Department of Dermatology, University of Szeged,
between 1 January 1999 and 31 December 2000. Following
preoperative lymphoscintigraphy (Tc-99m nanocoll) and
lymphatic mapping, sentinel nodes were successfully identi-
fied in all cases using both blue dye and radiolabelled colloid
with a gamma probe.8–10 Both primary tumours and sentinel
nodes were analysed histologically in serial sections of
paraffin-embedded specimens using haematoxylin and eosin
staining and immunohistochemistry for HMB-45 and S-100
antibodies by two well-trained dermatopathologists independ-
ently.10 For the definition of regression we used the criteria
suggested by the Pathological Group of the World Health
Organization Melanoma Programme. This includes the pres-
ence of a zone of tumour-free epidermis and dermis in which
there is fibrosis, often along with inflammation and dilated
vessels, flanked on one or both sides by tumour.11
Among the 134 patients with melanoma, 31 (23%) had
positive SNB. There were 89 patients with CMM < 1 mm
thick, of whom 12 (13%) had positive SNB. The false-negative
rate was 3Æ1% and the specificity 97%. The false-negative rate
is defined as the number of false-negative sentinel node
procedures (SNB negative with disease progression) divided
by the sum of true-positive (SNB positive) and false-negative
procedures: [1 ⁄ (31 + 1)] · 100%. The sensitivity is
defined as the number of true-positive procedures divided
by the sum of true-positive and false-negative SNB cases:
[31 ⁄ (31 + 1)] · 100%. The patients in our study underwent
follow-up visits every 3 months. The median follow up was
36 months (range 24–48).
Sentinel node metastases were found in a significantly
greater proportion among patients with primary tumours
showing histological evidence of regression: 14 of 22 (64%)
vs. 17 of 112 (15%) positive cases in patients with regressing
and nonregressing melanomas, respectively. The relative risk
of SNB positivity for patients with regressing tumours was
9Æ779 (95% confidence interval 3Æ56–26Æ862) compared with
patients with nonregressing tumours. Furthermore, of the 14
SNB-positive patients with regressing melanomas, 11 had
tumours thinner than 1Æ0 mm (mean ± SD 0Æ682 ± 0Æ20;
range 0Æ380–0Æ912), and none of these were ulcerated or had
infiltrated deeper than the papillary dermis (Clark level II).
These findings indicate that early in their disease course,
patients with relatively thin but regressing melanomas are at an
almost 10 times higher relative risk of developing regional
lymph node metastases than are patients with nonregressing
melanomas. It is possible that histological regression results in a
decreased Breslow thickness measurement, and thus in some
cases an erroneously more favourable prognostic estimate.
Although melanoma regression has been reported to be
associated with higher metastatic potential,4 to date no direct
evidence has been published to the effect that histological
regression predicts an increased risk of nodal involvement.
Currently, for patients with primary melanoma < 1Æ0 mm
thick, SNB is only indicated if ulceration or deep infiltration
(Clark level IV–V) is present.10,12 Our results suggest that
patients with thin melanomas showing histological signs of
regression should be considered as potential candidates for SNB.
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Oral pyoderma gangrenosum
SIR, Pyoderma gangrenosum (PG) is an uncommon disease
characterized by the occurrence of chronic ulcerations on the
skin. This condition is associated with a systemic illness in
approximately 50% of cases, with rheumatoid polyarthritis,
inflammatory bowel disease and haematological disorders
being the most frequent related diseases. Oral PG is rare and is
associated with cutaneous lesions in the vast majority of
cases. We report a patient with PG affecting exclusively the
oral mucosa.
An 84-year-old woman presented with a painful, extensive
oral ulceration first noticed 3 months previously. She had a
history of high blood pressure and osteoarthritis. She had no
other cutaneous lesions. Examination showed an extensive
ulceration affecting the right soft and hard palate and right
tonsil (Fig. 1a). Several biopsy specimens revealed a dense
neutrophilic infiltrate in the lamina propria of the mucosae
and a mixed inflammatory cell infiltrate in the deeper area
without signs of vasculitis (Fig. 1b). Periodic acid-Schiff and
Gram stains were negative. Direct immunofluorescence study
was not performed. Laboratory tests were as follows. Full
blood cell count: erythrocytes 2Æ9 · 1012 L)1; haemoglobin
9Æ7 g dL)1; mean corpuscular volume 101Æ2 fL; leucocytes
5Æ92 · 109 L)1 (78Æ4% neutrophils, 17Æ5% lymphocytes,
2Æ4% monocytes); platelets 165 · 109 L)1; erythrocyte sedi-
mentation rate 91 mm in the first hour (normal < 30).
Biochemistry: albumin 29 g L)1; aspartate aminotransferase
45 U L)1 (normal < 37); alanine aminotransferase 52 U L)1
(normal < 40); c-glutamyl transferase 1507 U L)1 (normal
< 50); alkaline phosphatase 2859 U L)1 (normal < 279);
glucose, urea, creatinine and the remaining parameters were
normal. Antinuclear and antimicrosomal antibodies were
negative, as was viral hepatitis serology. Ultrasonography
excluded macroscopic biliary causes of cholestasis. The
patient was on amiloride and hydrochlorothiazide, two
antihypertensive drugs that have not been reported to cause
cholestasis. The family of the patient refused any further
studies, such as liver biopsy, to clarify abnormal liver function
Figure 1. (a) Extensive, 4 · 2Æ5 cm ulceration of the hard and soft
palate and right tonsil. (b) The inflammatory infiltrate within the
lamina propria showed a conspicuous neutrophilic component with
no signs of vasculitis (haematoxylin and eosin; original magnifica-
tion · 40).
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